Impact of Respiratory Allergy on Response to Initiation of Biotherapy in Severe Asthma in Adult Severe Asthmatic Patients Followed at Poitiers University Hospital on Biotherapy
NCT06916104 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-04-08
Summary
The aim of this study is to take stock of the situation of adult patients with severe asthma on biotherapy, followed up at Poitiers University Hospital, and in particular to increase our knowledge of factors predictive of response to biotherapy. The main aim is to improve the management of adult severe asthma patients treated with biotherapy, according to their allergic status.
Conditions
- Severe Asthma
- Biotherapy
- Respiratory Allergy
Interventions
- OTHER
-
search for respiratory allergies
analyses in terms of biotherapy and respiratory allergy
Sponsors & Collaborators
-
Poitiers University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-01
- Primary Completion
- 2025-03-31
- Completion
- 2025-03-31
Countries
- France
Study Locations
More Related Trials
-
Phenotypic and Functional Characterization of Neutrophils and Eosinophils in Severe Asthma Treated With Biotherapy
NCT05972213 ·Status: RECRUITING
-
Cohort Analysis of Clinical and Biological Severe Childhood Asthma
NCT02114034 ·Status: ACTIVE_NOT_RECRUITING
-
Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma
NCT01362621 ·Status: COMPLETED
-
Bronchial Thermoplasty in Severe Asthma With Frequent Exacerbations
NCT02464995 ·Status: UNKNOWN ·Phase: NA
-
A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)
NCT05070663 ·Status: COMPLETED
-
Follow-up of Children With Severe Asthma at Adult Age
NCT05032209 ·Status: UNKNOWN
-
Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
NCT04520165 ·Status: ACTIVE_NOT_RECRUITING
-
Inhaler Adherence in Severe Unstable Asthma
NCT02307669 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of the Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled Air
NCT03988790 ·Status: UNKNOWN ·Phase: NA
-
A Study to Compare Severe Asthma Patients Who Start Biologics and Who do Not Start (PROSPECT)
NCT04808518 ·Status: COMPLETED
-
Taiwan Severe Asthma Biologic Registry
NCT06456450 ·Status: RECRUITING
-
Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium
NCT04221802 ·Status: COMPLETED
-
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
NCT01312961 ·Status: COMPLETED ·Phase: PHASE2
-
Experience of Biologic Treatments for Severe Asthma: a Survey
NCT06903780 ·Status: RECRUITING
-
Immune Interactions in Severe Asthma
NCT02566668 ·Status: COMPLETED
-
Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
NCT03833141 ·Status: COMPLETED
-
An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe Asthma
NCT06064526 ·Status: COMPLETED
-
Intense Airway Eosinophilia in Asthma
NCT03696914 ·Status: COMPLETED
-
CYT003-QbG10 for Treatment of Allergic Asthma Bronchial
NCT00890734 ·Status: COMPLETED ·Phase: PHASE2
-
Withdrawal of Dupilumab in Severe Asthma
NCT06818019 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
BenRalizumab Effect on Airway Remodeling in Severe asTHma
NCT06288516 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma
NCT03782532 ·Status: COMPLETED ·Phase: PHASE3
-
Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions
NCT04184284 ·Status: COMPLETED
-
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
NCT07309614 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma
NCT00598104 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2